Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralising antibody, in combination with exemestane and everolimus in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer: Preliminary results of the Phase 1b part

被引：0
|
作者：
Cortes, J. [1 ,2 ]
Martinez Janesz, N. [1 ]
Sablin, M. P. [3 ]
Perez-Fidalgo, J. A. [4 ]
Neven, P. [5 ]
Hedayati, E. [6 ,7 ]
Ballester, A. [8 ]
Ehrhart, M. P. [9 ,10 ]
Huang, D. Chin-Lun [11 ]
Bogenrieder, T. [12 ]
Schmid, P. [13 ]
机构：
[1] Ramon y Cajal Univ Hosp, Dept Med Oncol, Madrid, Spain
[2] Vall dHebron Inst Oncol VHIO, Dept Oncol, Barcelona, Spain
[3] Inst Curie, Dept Med Oncol, Paris, France
[4] Hosp Clin Univ Valencia, Dept Haematol & Med Oncol, Valencia, Spain
[5] UZ Leuven, Multidisciplinary Breast Ctr, Leuven, Belgium
[6] Karolinska Inst, Stockholm, Sweden
[7] Univ Hosp, Dept Oncol Pathol, Stockholm, Sweden
[8] Boehringer Ingelheim Espana SA, Dept Med Oncol, Barcelona, Spain
[9] Staburo GmbH, Munich, Germany
[10] Boehringer Ingelheim Pharma GmbH & Co KG, St Joseph, MO USA
[11] Boehringer Ingelheim Taiwan Ltd, Med, Taipei, Taiwan
[12] Boehringer Ingelheim RCV, Med, Vienna, Austria
[13] Queen Mary Univ London, Ctr Expt Canc Med, Barts Canc Inst, London, England
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
389
引用
收藏
页码：S112 / S112
页数：1
相关论文
共 50 条
  • [1] Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR plus ) locally advanced or metastatic breast cancer (BC): primary phase lb results.
    Cortes, Javier
    Janez, Noelia Martinez
    Sablin, Marie-Paule
    Perez-Fidalgo, Jose Alejandro
    Neven, Patrick
    Hedayati, Elham
    Ballester, Alexandra
    Ehrhart, Marie-Paule
    Huang, Dennis C.
    Bogenrieder, Thomas
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Xentuzumab (BI 836845), an insulin-like growth factor (IGF)-neutralizing antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR plus ) locally advanced/metastatic breast cancer (LA/mBC): Randomized phase 2 results
    Crown, J.
    Sablin, M-P
    Cortes, J.
    Bergh, J.
    Im, S-A
    Lu, Y-S
    Martinez, N.
    Neven, P.
    Lee, K. S.
    Morales, S.
    Perez-Fidalgo, J. A.
    Adamson, D.
    Goncalves, A.
    Prat, A.
    Jerusalem, G.
    Schlieker, L.
    Espadero, R-M
    Bogenrieder, T.
    Huang, D. Chin-Lun
    Schmid, P.
    CANCER RESEARCH, 2019, 79 (04)
  • [3] Xentuzumab (BI 836845), an IGF-neutralizing antibody, combined with exemestane and everolimus in hormone receptor-positive (HR plus ) locally advanced/metastatic breast cancer: Randomised phase 2 results
    Crown, John
    Sablin, Marie-Paule
    Cortes, Javier
    Bergh, Jonas
    Im, Seock-Ah
    Lu, Yen-Shen
    Martinez, Noelia
    Neven, Patrick
    Lee, Keun Seok
    Morales, Serafin
    Alejandro Perez-Fidalgo, J.
    Adamson, Douglas
    Goncalves, Anthony
    Prat, Aleix
    Jerusalem, Guy
    Schlieker, Laura
    Espadero, Rosa-Maria
    Bogenrieder, Thomas
    Huang, Dennis Chin-Lun
    Schmid, Peter
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 173 - 173
  • [4] Xentuzumab (BI 836845), an IGF-neutralizing antibody, combined with exemestane and everolimus in hormone receptor-positive (HR plus ) locally advanced/metastatic breast cancer: Randomized Phase 2 Results
    Crown, John
    Sablin, Marie-Paule
    Cortes, Javier
    Bergh, Jonas
    Im, Seock-Ah
    Lu, Yen-Shen
    Martinez, Noelia
    Neven, Patrick
    Lee, Keun Seok
    Morales, Serafin
    Perez-Fidalgo, J. Alejandro
    Adamson, Douglas
    Goncalves, Anthony
    Prat, Aleix
    Jerusalem, Guy
    Schlieker, Laura
    Espadero, Rosa-Maria
    Bogenrieder, Thomas
    Huang, Dennis Chin-Lun
    Schmid, Peter
    BRITISH JOURNAL OF CANCER, 2019, 121 : 20 - 20
  • [5] A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
    Peter Schmid
    Marie-Paule Sablin
    Jonas Bergh
    Seock-Ah Im
    Yen-Shen Lu
    Noelia Martínez
    Patrick Neven
    Keun Seok Lee
    Serafín Morales
    J. Alejandro Pérez-Fidalgo
    Douglas Adamson
    Anthony Gonçalves
    Aleix Prat
    Guy Jerusalem
    Laura Schlieker
    Rosa-Maria Espadero
    Thomas Bogenrieder
    Dennis Chin-Lun Huang
    John Crown
    Javier Cortés
    Breast Cancer Research, 23
  • [6] A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
    Schmid, Peter
    Sablin, Marie-Paule
    Bergh, Jonas
    Im, Seock-Ah
    Lu, Yen-Shen
    Martinez, Noelia
    Neven, Patrick
    Lee, Keun Seok
    Morales, Serafin
    Perez-Fidalgo, J. Alejandro
    Adamson, Douglas
    Goncalves, Anthony
    Prat, Aleix
    Jerusalem, Guy
    Schlieker, Laura
    Espadero, Rosa-Maria
    Bogenrieder, Thomas
    Huang, Dennis Chin-Lun
    Crown, John
    Cortes, Javier
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [7] Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer
    Murtuza Rampurwala
    Kari B. Wisinski
    Mark E. Burkard
    Sima Ehsani
    Ruth M. O’Regan
    Lakeesha Carmichael
    KyungMann Kim
    Jill Kolesar
    Amye J. Tevaarwerk
    Investigational New Drugs, 2017, 35 : 87 - 94
  • [8] Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR plus ) metastatic breast cancer
    Rampurwala, Murtuza
    Wisinski, Kari B.
    Burkard, Mark E.
    Ehsani, Sima
    O'Regan, Ruth M.
    Carmichael, Lakeesha
    Kim, KyungMann
    Kolesar, Jill
    Tevaarwerk, Amye J.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) : 87 - 94
  • [9] Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR plus ) metastatic breast cancer.
    Rampurwala, Murtuza M.
    Burkard, Mark E.
    Wisinski, Karl Braun
    Chimeh, Sima Ehsani
    Zeal, Jamie
    Koehn, Tamara
    Champeny, Tone L.
    Rettig, Joan
    Kim, KyungMann
    Kolesar, Jill
    Tevaarwerk, Amye
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
    Tolaney, Sara M.
    Beeram, Muralidhar
    Beck, J. Thaddeus
    Conlin, Alison
    Dees, E. Claire
    Puhalla, Shannon L.
    Rexer, Brent N.
    Burris, Howard A., III
    Jhaveri, Komal
    Helsten, Teresa
    Becerra, Carlos
    Kalinsky, Kevin
    Moore, Kathleen N.
    Manuel, Allison M.
    Lithio, Andrew
    Price, Gregory L.
    Chapman, Sonya C.
    Litchfield, Lacey M.
    Goetz, Matthew P.
    FRONTIERS IN ONCOLOGY, 2022, 11
12345